Want to see CLBT full AI Analyst Report?
CLBT Stock Chart & Stats
$14.22
$0.43(2.99%)
At close: 4:00 PM EDT
$14.22
$0.43(2.99%)
Day’s Range― - ―
52-Week Range$9.58 - $19.98
Previous Close$14.92
Volume902.96K
Average Volume (3M)1.82M
Market Cap
$2.76B
Enterprise Value$3.27K
Total Cash (Recent Filing)$442.53M
Total Debt (Recent Filing)$23.23M
Price to Earnings (P/E)48.8
Beta0.74
Next Earnings
Nov 18, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding249,439,820
10 Day Avg. Volume1,393,342
30 Day Avg. Volume1,818,489
Financial Highlights & Ratios
PEG Ratio-0.47
Price to Book (P/B)9.30
Price to Sales (P/S)9.47
P/FCF Ratio28.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.75Price Target Upside10.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.33
Revenue Forecast (FY)$563.32M
Bulls Say, Bears Say
Bulls Say
Subscription-led Recurring GrowthStrong ARR growth and a subscription-heavy revenue mix improve visibility, retention potential and scalability. Recurring software revenue can support durable expansion as agencies add users, modules and analytical capabilities.
High Margins And Cash GenerationVery high gross margins and robust free cash flow indicate attractive software economics and internal funding capacity. This supports continued product investment, customer support and growth without relying heavily on external capital.
Conservative Balance SheetMinimal leverage and substantial liquidity provide resilience through uneven procurement cycles and flexibility to invest in platform development. The balance sheet also reduces refinancing risk as Cellebrite expands its product portfolio.
Bears Say
Lowered Growth OutlookThe guidance reset indicates that near-term expansion is less predictable than previously expected. Slower deal conversion and lower expansion assumptions may weigh on recurring growth while management rebuilds execution confidence.
Procurement And Deal-timing DependenceDependence on a limited number of complex public-sector and cloud transactions creates uneven quarterly conversion. Administrative requirements and elongated procurement cycles can delay ARR recognition and make forecasting less reliable.
Uneven Earnings And Cash-flow ConsistencyRecent profitability is strong, but the historical swing in earnings and softer free-cash-flow growth show that performance has not been consistently stable. This may limit confidence in the durability of current margins and conversion.
Cellebrite DI News
CLBT FAQ
What was Cellebrite DI’s price range in the past 12 months?
Cellebrite DI lowest stock price was $9.58 and its highest was $19.98 in the past 12 months.
What is Cellebrite DI’s market cap?
Cellebrite DI’s market cap is $2.76B.
When is Cellebrite DI’s upcoming earnings report date?
Cellebrite DI’s upcoming earnings report date is Nov 18, 2026 which is in 85 days.
How were Cellebrite DI’s earnings last quarter?
Cellebrite DI released its earnings results on Aug 13, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.059 by -$0.039.
Is Cellebrite DI overvalued?
According to Wall Street analysts Cellebrite DI’s price is currently Undervalued.
Does Cellebrite DI pay dividends?
Cellebrite DI does not currently pay dividends.
What is Cellebrite DI’s EPS estimate?
Cellebrite DI’s EPS estimate is 0.09.
How many shares outstanding does Cellebrite DI have?
Cellebrite DI has 249,439,820 shares outstanding.
What happened to Cellebrite DI’s price movement after its last earnings report?
Cellebrite DI reported an EPS of $0.02 in its last earnings report, missing expectations of $0.059. Following the earnings report the stock price went down -29.18%.
Which hedge fund is a major shareholder of Cellebrite DI?
Currently, no hedge funds are holding shares in CLBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cellebrite DI Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (10.76% Upside)
$15.75 (10.76% Upside)
Blogger Sentiment
Bullish
CLBT Sentiment 63%
Sector Average 59%
Sector Average 59%
Hedge Fund Trend
Decreased
By 230.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.5%
Last 30 Days ▲ 13.7%
Last 30 Days ▲ 13.7%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
26.27%
Trailing 12-Months
Company Description
Cellebrite DI
Cellebrite DI Ltd. delivers specialized digital intelligence solutions crafted for legally authorized investigations. Their comprehensive DI platform enables users to efficiently gather, scrutinize, interpret, and oversee digital information throughout the investigative process. These essential tools are utilized in a wide array of scenarios, including cases involving child exploitation, homicides, counter-terrorism operations, border control, sexual offenses, human trafficking, corporate security incidents, intellectual property theft, and civil litigation. A key offering, the Universal Forensic Extraction Device (UFED), is engineered to surmount significant hurdles in accessing digital evidence, such as intricate device locks, encryption barriers, deleted data, and obscure content that might otherwise conceal crucial information. The company also provides Seeker, designed for analyzing video footage; OSINT Analyze, a real-time deep-dive tool for examining open-source information across the surface, deep, and dark web; and Crypto Tracer, which deciphers blockchain transactions alongside related data from numerous sources to identify and categorize digital wallets and activities. Cellebrite's clientele includes federal, state, and local government bodies, as well as various enterprise companies and service providers. Established in 1999 and headquartered in Petah Tikva, Israel, the firm operates internationally with a footprint in countries such as the United States, Germany, Singapore, Australia, Brazil, the United Kingdom, France, Canada, Japan, and India. Additionally, Cellebrite Mobile Synchronization Ltd. functions as a subsidiary of Sun Corporation.
CLBT Company Deck
CLBT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call was mixed. The company reported strong underlying metrics (ARR +21%, revenue +16%, high gross margin and improved EBITDA guidance), meaningful new-product traction (Genesis, Guardian, Advanced Unlocks) and healthy cash/FCF. However, execution and timing issues on several large, cloud/AI deals—driven by new procurement and foreign-entity requirements and lower-than-expected ARR uplift from Insights conversions—led management to lower full-year ARR guidance and caution on near-term growth. Management emphasized improved sales rigor, tighter forecasting, and disciplined cost management, suggesting the company is addressing issues while maintaining confidence in long-term opportunity.View all CLBT earnings summariesCLBT Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$15.75
▲(10.76% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
0.85% Insiders
7.77% Mutual Funds
35.10% Other Institutional Investors
54.37% Public Companies and
Individual Investors









